MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) shares dropped 3.9% during mid-day trading on Friday . The company traded as low as $1.18 and last traded at $1.35. Approximately 124,355 shares changed hands during mid-day trading, an increase of 100% from the average daily volume of 62,257 shares. The stock had previously closed at $1.41.
Analyst Upgrades and Downgrades
Separately, B. Riley cut their price objective on MiNK Therapeutics from $10.00 to $7.00 in a report on Wednesday, May 11th.
MiNK Therapeutics Trading Down 3.9 %
The firm has a fifty day moving average of $1.47 and a two-hundred day moving average of $2.14.
Institutional Investors Weigh In On MiNK Therapeutics
A hedge fund recently bought a new stake in MiNK Therapeutics stock. Sofinnova Investments Inc. bought a new stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 345,499 shares of the company’s stock, valued at approximately $1,541,000. Sofinnova Investments Inc. owned 1.03% of MiNK Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 3.99% of the company’s stock.
MiNK Therapeutics Company Profile
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.